Anzeige
Mehr »
Login
Mittwoch, 29.01.2025 Börsentäglich über 12.000 News von 683 internationalen Medien
Energiekrise als Chance: Mit dieser Aktie starten Sie ins Börsenjahr 2025 durch!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
PR Newswire
519 Leser
Artikel bewerten:
(2)

EuroEyes International Eye Clinic Limited: EuroEyes signs tri-party agreement of mutual cooperation with leading medical universities in the PRC and Germany

Finanznachrichten News

Collaboration aims to drive innovation and nurture talent that could help power sustainable business growth for the company

HONG KONG, July 29, 2022 /PRNewswire/ -- EuroEyes International Eye Clinic Limited ("EuroEyes" or the "Company", together with its subsidiaries, the "Group", HKEX: 1846) announced on 27 July that it has signed a tri-party agreement of mutual cooperation ("AMC") with the Eye Center of Second Affiliated Hospital Zhejiang University School of Medicine, Zhejiang University Eye Hospital and The David J. Apple International Laboratory for Ocular Pathology & International Vision Correction Research Centre (IVCRC), University Eye Clinic of the Ruprecht-Karls-University of Heidelberg. The AMC aims to establish closer cooperation between eye care professionals in the PRC and Germany that could foster new innovations in ophthalmology, and enhance the skills of surgeons at EuroEyes and in the two countries who could contribute to the continued development in eye care.

(Top): Prof. WANG Jian'an (Bottom left to right): JIN Xiuming; Prof. HUANG Jian; Prof. YAO Ke; YANG Mingli, Prof. Dr. Gerd U. Auffarth; Dr. med. Jørn S. Jørgensen; Prof. Dr. Michael Knorz (PRNewsfoto/EuroEyes International Eye Clinic Limited)

The online signing ceremony was co-chaired by Prof. HUANG Jian, Executive Vice President of The Second Affiliated Hospital Zhejiang University School of Medicine and Prof. Dr. Gerd U. Auffarth, Chairman of University Eye Clinic of the Ruprecht-Karls-University of Heidelberg. Other representatives from China include Prof. WANG Jian'an, Head of The Second Affiliated Hospital Zhejiang University School of Medicine; Prof. YAO Ke, and JIN Xiuming, the Chair and Deputy-Chair of Eye Center of The Second Affiliated Hospital Zhejiang University School of Medicine; YANG Mingli, Director of International Affairs Office of The Second Affiliated Hospital Zhejiang University School of Medicine and Mr. Michael ZHANG, COO of China of EuroEyes International Clinics. The German representatives are Dr. med. Jørn S. Jørgensen, Founder, Chairman and CEO of EuroEyes and Prof. Dr. Michael Knorz, EuroEyes Senior Vice President and Professor of Ophthalmology at University of Heidelberg, Medical Faculty Mannheim.

The AMC includes joint participation in respective scientific and educational activities, such as research projects and publication of findings, advocacy campaigns, and organisation of conferences, all of which to help discover breakthroughs in ophthalmology.

All parties will also establish an exchange programme for young doctors to conduct scientific research, improve surgical skills, and share experiences in the different locations. Ophthalmologists from EuroEyes, Heidelberg University Eye Clinic and Second Affiliated Hospital of Zhejiang University School of Medicine will have the opportunity to pursue a 3 to 6 months fellowship in the PRC and Germany.

Participants from the PRC will be able to pursue a PhD thesis and gain experience at an EuroEyes clinic in Germany; those from Germany will be able to participate in research projects and are enabled to perform surgery to improve their experiences in intraocular lens surgery, laser vision correction and cataract complication management.

Dr. med. Jørn S. Jørgensen, Founder, Chairman and CEO of EuroEyes, said: "We are excited to foster the alliances of medical and science development among EuroEyes, Second Affiliated Hospital of Zhejiang University School of Medicine and Heidelberg University Eye Clinic. We believe the collaboration will help EuroEyes identify talented students and surgeons in the PRC, offering them with local understandings, postgraduate experiences and knowledge exchanges in Germany. Meanwhile, surgeons in Germany will be given opportunities to possess a wealth of on-the-ground experience in the PRC. This programme could help EuroEyes address any unmet medical needs in both markets, while at the same time help nurture a new generation of eye doctors. We will put a lot of effort into this collaboration and we look forward to working together."

Professor Yao Ke, Chair of Eye Center of Second Affiliated Hospital Zhejiang University School of Medicine, Zhejiang University Eye Hospital, said: "Zhejiang University has kept a close relationship with Heidelberg University and the experts from EuroEyes for the past decades, and today we are pleased to witness this crucial moment of taking our collaboration to a next level. The new fellowship programme will help train a large number of medical students and refractive surgeons, furnish them with excellent trainings and years of surgical experiences from both countries. This would allow us to share the best practices and together discover medical breakthroughs in ophthalmology, all of which will benefit patients worldwide."

Professor Dr. Gerd U. Auffarth, Chairman of University Eye Clinic of the Ruprecht-Karls-University of Heidelberg, said: "This AMC is an all-win situation for the three parties and we are pleased to be part of it. It is a remarkable achievement to gather ophthalmology, education and entrepreneurship at this high level. With the support from Dr. Jørgensen, who is the creative power behind the collaboration, the exchange between PhD students and doctors from all parties could be carried out in a more formalised way. As Dr. Jørgensen brought the excellence of German ophthalmology to China, we are delighted to have Chinese ophthalmologists in Germany to share their expertise and know-hows. This AMC will certainly lead us to a bright future and we look forward to working together."

Dr. Jørn S. Jørgensen added: "Despite the challenges brought by severe COVID-19 situations in China and unfavourable global environment in the first half of the year, we managed to remain resistant to the external challenges. We have been prudent in our expansion plan, strive to improve our profitability, and maintain a healthy cash flow. With our far-reaching geographical coverage with operations in Germany, China, Denmark and United Kingdom, which helps diversity potential business risks from a single market, we are confident in the sustainable growth of the Group."

For more information, please contact:

Hume Brophy Communications - Ashley So / Jane Hung / Connie Chan, euroeyeshk@humebrophy.com

Photo - https://mma.prnewswire.com/media/1869137/Top__Prof_WANG_Jian_an__Bottom_left_right__JIN_Xiuming__Prof.jpg

© 2022 PR Newswire
Gewinner im Megamarkt
Biotechnologie ist eine der bedeutendsten Zukunftstechnologien unserer Zeit. Zahlreiche Biotechnologie- und Pharmakonzerne haben sich unter anderem dem Kampf gegen Tumorerkrankungen verschrieben. Der weltweite Markt für Krebsmedikamente verzeichnet ein stetiges Wachstum. Für das Jahr 2025 wird ein Umsatz von etwa 190,3 Milliarden Euro prognostiziert, mit einer erwarteten jährlichen Wachstumsrate von 6,42% bis 2029, was zu einem geschätzten Marktvolumen von 244,1 Milliarden Euro führen würde.

Wir haben 3 aussichtsreiche Biotechnologieaktien mit Schwerpunkt Erforschung und Entwicklung von Wirkstoffen gegen Tumorerkrankungen ausfindig gemacht, die in den kommenden Monaten und Jahren erhebliches Aufwärtspotenzial versprechen und Vervielfachungspotenzial besitzen.

Fordern Sie jetzt unseren neuen kostenlosen Spezialreport an und erfahren Sie, welche 3 Biotech-Aktien durchstarten und zu Ihrem Börsenerfolg in 2025 beitragen könnten!
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.